about
Dietary phenolics against colorectal cancer--From promising preclinical results to poor translation into clinical trials: Pitfalls and future needs.Neuroprotective Effects of Bioavailable Polyphenol-Derived Metabolites against Oxidative Stress-Induced Cytotoxicity in Human Neuroblastoma SH-SY5Y Cells.Antiproliferative activity of the ellagic acid-derived gut microbiota isourolithin A and comparison with its urolithin A isomer: the role of cell metabolism.Comprehensive characterization of the effects of ellagic acid and urolithins on colorectal cancer and key-associated molecular hallmarks: MicroRNA cell specific induction of CDKN1A (p21) as a common mechanism involved.Urolithins, the rescue of "old" metabolites to understand a "new" concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status.Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells.In vivo relevant mixed urolithins and ellagic acid inhibit phenotypic and molecular colon cancer stem cell features: A new potentiality for ellagitannin metabolites against cancer.Gene expression changes in colon tissues from colorectal cancer patients following the intake of an ellagitannin-containing pomegranate extract: a randomized clinical trial.MicroRNAs expression in normal and malignant colon tissues as biomarkers of colorectal cancer and in response to pomegranate extracts consumption: Critical issues to discern between modulatory effects and potential artefacts.[Introduction of capillary glycosylated haemoglobin determination in a Primary Care Health Area: Multicentre study of the evolution of patients with type 2 diabetes mellitus].[The figure of a nurse educator improves HbA1c levels and lipid profile in patients with type 1 diabetes].Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patientsConsumption of pomegranate decreases plasma lipopolysaccharide-binding protein levels, a marker of metabolic endotoxemia, in patients with newly diagnosed colorectal cancer: a randomized controlled clinical trial
P50
Q38360706-7B5DB691-DBD1-486D-90A9-2A042C1CF32EQ38718590-80421209-AC8B-4AE9-98F9-7A8D3F9FEF49Q38810847-425F5F12-31B6-40B6-BE09-0C7C1DC3428BQ38814531-1C4CE405-C2D1-44A2-859D-387986280BAAQ38829534-3027BD4A-9FEF-4E23-AF9F-26539356106AQ39090075-18954E7C-7DC3-44B2-B4D6-8ECD2CCBB243Q39904723-7D632E1E-0B24-47B0-9FD0-1654587F99E4Q52726937-DF113BA6-2066-4D07-AFB5-465BAB08FBBDQ53456657-4228548A-0E0C-4C0B-89C8-9C480C96BEABQ53553543-E3BC4847-AA41-4CD0-83E4-9007F752BB4DQ54311310-199ED38A-8CB9-4067-8AB0-5B019BE5A525Q57759687-816599F8-9CC1-4420-8070-56D9357EDA8DQ61988085-A30A3EE2-D235-490F-AB3E-ED34CD1EBAC2
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
María A Nuñez-Sánchez
@en
María A Nuñez-Sánchez
@nl
type
label
María A Nuñez-Sánchez
@en
María A Nuñez-Sánchez
@nl
prefLabel
María A Nuñez-Sánchez
@en
María A Nuñez-Sánchez
@nl
P31
P496
0000-0002-8938-2767